The role of endogenous and exogenous enzymes in chronic wounds: A focus on the implications of aberrant levels of both host and bacterial proteases in wound healing

Wound Repair and Regeneration

Volumn 20, Issue 2, 2012, Pages 125-136

  McCarty, Sara M ^a   Cochrane, Christine A ^a   Clegg, Peter D ^a   Percival, Steven L ^b,c  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b WEST VIRGINIA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Advanced Medical Solutions   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CELL PROTEIN; COLLAGENASE 3; ELASTASE; GELATINASE A; GELATINASE B; INTERSTITIAL COLLAGENASE; MATRILYSIN; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE 14; PROTEINASE; STROMELYSIN 2; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

CELL GROWTH; CHRONIC WOUND; DEGRADATION; ENZYME REGULATION; EXTRACELLULAR MATRIX; FIBROBLAST; HOST CELL; HUMAN; IMMUNOCOMPETENT CELL; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PSEUDOMONAS AERUGINOSA; REVIEW; SCAR; TISSUE INJURY; UPREGULATION; WOUND CARE; WOUND FLUID; WOUND HEALING; WOUND HEALING IMPAIRMENT; WOUND INFECTION;

BIOFILMS; CICATRIX; DIABETIC FOOT; EXTRACELLULAR MATRIX; EXUDATES AND TRANSUDATES; HUMANS; LEUKOCYTE ELASTASE; MATRIX METALLOPROTEINASES; PRESSURE ULCER; UP-REGULATION; VARICOSE ULCER; WOUND HEALING;

EID: 84858126311     PISSN: 10671927     EISSN: 1524475X     Source Type: Journal    
DOI: 10.1111/j.1524-475X.2012.00763.x     Document Type: Review

References (122)

1. Werner S, Grose R,. Regulation of wound healing by growth factors and cytokines. Physiol Rev 2003; 83: 835-870. (Pubitemid 36828927)
2. Martin P,. Wound healing-aiming for perfect skin regeneration. Science 1997; 276: 75.
3. Singer AJ, Clark R,. Cutaneous wound healing. N Engl J Med 1999; 341: 738-746. (Pubitemid 29407375)
4. Mustoe T,. Dermal ulcer healing: advances in understanding. Meeting: tissue repair and ulcer/wound healing: molecular mechanisms, therapeutic targets and future directions. Paris, France, March 17-18, 2005.
5. Harding K, Morris H, Patel G,. Healing chronic wounds. BMJ 2002; 324: 160.
6. Diegelmann RF, Evans MC,. Wound healing: an overview of acute, fibrotic and delayed healing. Front Biosci 2004; 9: 283-289. (Pubitemid 38925460)
7. Bosman FT, Stamenkovic I,. Functional structure and composition of the extracellular matrix. J Pathol 2003; 200: 423-428. (Pubitemid 36818243)
8. Eming SA, Krieg T, Davidson JM,. Inflammation in wound repair: molecular and cellular mechanisms. J Invest Dermatol 2007; 127: 514-525.
9. Simpson DM, Ross R,. The neutrophilic leukocyte in wound repair: a study with antineutrophil serum. J Clin Invest 1972; 51: 2009-2023.
10. Yager DR, Nwomeh BC,. The proteolytic environment of chronic wounds. Wound Rep Reg 1999; 7: 433-441. (Pubitemid 30027565)
11. Garner W, Rodriguez J, Miller C, Till G, Rees R, Smith D, Remick D,. Acute skin injury releases neutrophil chemoattractants. Surgery 1994; 116: 42.
12. Hettiaratchy S, Dziewulski P,. ABC of burns: introduction. BMJ 2004; 328: 1366.
13. Courtney BA, Ruppman JB, Cooper HM,. Save our skin: initiative cuts pressure ulcer incidence in half. J Nurs Manag 2006; 37: 36.
14. Mustoe T,. Understanding chronic wounds: a unifying hypothesis on their pathogenesis and implications for therapy. Am J Surg 2004; 187: S65-70.
15. Supp DM, Boyce ST,. Engineered skin substitutes: practices and potentials. Clin Dermatol 2005; 23: 403-412. (Pubitemid 40968113)
16. Raghow R,. The role of extracellular matrix in postinflammatory wound healing and fibrosis. FASEB J 1994; 8: 823.
17. Kleinman HK, Philp D, Hoffman MP,. Role of the extracellular matrix in morphogenesis. Curr Opin Biotechnol 2003; 14: 526-532. (Pubitemid 37298039)
18. Badylak SF,. The extracellular matrix as a scaffold for tissue reconstruction. Semin Cell Dev Biol 2002; 13: 377-383. (Pubitemid 35300815)
19. Clark RAF, Lanigan JM, DellaPelle P, Manseau E, Dvorak HF, Colvin RB,. Fibronectin and fibrin provide a provisional matrix for epidermal cell migration during wound reepithelialisation. J Invest Dermatol 1982; 79: 264-269. (Pubitemid 12005678)
20. Greiling D, Clark RA,. Fibronectin provides a conduit for fibroblast transmigration from collagenous stroma into fibrin clot provisional matrix. J Cell Sci 1997; 110: 861-870. (Pubitemid 27196785)
21. Bayat A, McGrouther D, Ferguson M,. Skin scarring. BMJ 2003; 326: 88.
22. Cochrane C, Freeman K, Knottenbelt D,. Effect of growth factors on the characteristics of cells associated with equine wound healing and sarcoid formation. Wound Rep Reg 1996; 4: 58-65. (Pubitemid 126670837)
23. Jacobs K, Leach D, Fretz P, Townsend H,. Comparative aspects of the healing of excisional wounds on the leg and body of horses. Vet Surg 1984; 13: 83-90.
24. Brown J, Bayat A,. Genetic susceptibility to raised dermal scarring. Br J Dermatol 2009; 161: 8-18.
25. Werb Z,. ECM and cell surface proteolysis: minireview regulating cellular ecology. Cell 1997; 91: 439-442. (Pubitemid 27508232)
26. Palolahti M, Lauharanta J, Stephens RW, Kuusela P, Vaheri A,. Proteolytic activity in leg ulcer exudate. Exp Dermatol 1993; 2: 29-37. (Pubitemid 23244485)
27. Barrick B, Campbell EJ, Owen CA,. Leukocyte proteinases in wound healing: roles in physiologic and pathologic processes. Wound Rep Regen 1999; 7: 410-422. (Pubitemid 30027563)
28. Tarnuzzer RW, Schultz GS,. Biochemical analysis of acute and chronic wound environments. Wound Rep Regen 1996; 4: 321-325. (Pubitemid 126670847)
29. Yager DR, Chen SM, Ward SI, Olutoye OO, Diegelmann RF, Cohen K,. Ability of chronic wound fluids to degrade peptide growth factors is associated with increased levels of elastase activity and diminished levels of proteinase inhibitors. Wound Rep Regen 1997; 5: 23-32. (Pubitemid 127686717)
30. Wlaschek M, Peus D, Achterberg V, Meyer-Ingold W, Scharffetter-Kochanek K,. Protease inhibitors protect growth factor activity in chronic wounds. Br J Dermatol 1997; 137: 646-663.
31. Cole AM, Shi J, Ceccarelli A, Kim YH, Park A, Ganz T,. Inhibition of neutrophil elastase prevents cathelicidin activation and impairs clearance of bacteria from wounds. Blood 2001; 97: 297-304. (Pubitemid 32061273)
32. Sternlicht MD, Werb Z,. How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 2001; 17: 463.
33. Dumin JA, Dickeson SK, Stricker TP, Bhattacharyya-Pakrasi M, Roby JD, Santoro SA, Parks WC,. Pro-collagenase-1 (matrix metalloproteinase-1) binds the α2β1 integrin upon release from keratinocytes migrating on type 1 collagen. J Biol Chem 2001; 276: 29368-29374.
34. Kubo M, Van De Water L, Plantefaber LC, Mosessen MW, Simon M, Tonnesen MG, Taichman L, Clark RAF,. Fibrinogen and fibrin are anti-adhesive for keratinocytes: a mechanism for fibrin eschar slough during wound repair. J Invest Dermatol 2001; 117: 1369-1381. (Pubitemid 34032762)
35. Rømer J, Bugge TH, Fyke C, Lund LR, Flick MJ, Degen JL, Danø K,. Impaired wound healing in mice with a disrupted plasminogen gene. Nature Med 1996; 2: 287-292. (Pubitemid 26080649)
36. Lund LR, Rømer J, Bugge TH, Nielsen BS, Frandsen TL, Degen JL, Stephens RW, Danø K,. Functional overlap between two classes of matrix-degrading proteases in wound healing. EMBO J 1999; 18: 4645-4656. (Pubitemid 29415519)
37. Lijnen HR, Collen D,. Tissue-type plasminogen activator. Ann Biol Clin (Paris) 1987; 45: 198-201. (Pubitemid 17119652)
38. Morioka S, Lazarus GS, Baird JL, Jensen PJ,. Migrating keratinocytes express urokinase-type plasminogen activator. J Invest Dermatol 1987; 88: 418-423. (Pubitemid 17053084)
39. Romer J, Lund LR, Eriksen J, Pyke C, Kristensen P, Dano K,. The receptor for urokinase-type plasminogen activator is expressed by keratinocytes at the leading edge during re-epithelialization of mouse skin wounds. J Invest Dermatol 1994; 102: 519-522. (Pubitemid 24117196)
40. Salo T, Mäkelä M, Kylmäniemi M, Autio-Harmainen H, Larjava H,. Expression of matrix metalloproteinase-2 and -9 during early human wound healing. Lab Invest 1994; 70: 176.
41. Rowe RG, Weiss SJ,. Breaching the basement membrane: who, when and how? Trends Cell Biol 2008; 18: 560-574.
42. 1 receptor. J Invest Dermatol 2008; 128: 2783-2791.
43. Matsubara M, Zieske JD, Fini ME,. Mechanism of basement membrane dissolution preceding corneal ulceration. Invest Ophthalmol Vis Sci 1991; 32: 3221-3237.
44. Saarialho-Kere UK, Chang ES, Welgus H, Parks WC,. Distinct localization of collagenase and tissue inhibitor of metalloproteinases expression in wound healing associated with ulcerative pyogenic granuloma. J Clin Invest 1992; 90: 1952.
45. Saarialho-Kere U, Pentland A, Birkedal-Hansen H, Parks W, Welgus H,. Distinct populations of basal keratinocytes express stromelysin-1 and stromelysin-2 in chronic wounds. J Clin Invest 1994; 94: 79.
46. Ravanti L, Kähäri V,. Matrix metalloproteinases in wound repair (review). Int J Mol Med 2000; 6: 391.
47. Parks WC, Wilson CL, López-Boado YS,. Matrix metalloproteinases as modulators of inflammation and innate immunity. Nat Rev Immunol 2004; 4: 617-629. (Pubitemid 39025047)
48. Roeb E,. Matrix metalloproteinases. In:, Offermanns S, Rosenthal W, editors. Encyclopedia of molecular pharmacology. Heidelberg: Springer-Verlag, 2008: Part 13: 745-748.
49. Murphy G, Knäuper V,. Relating matrix metalloproteinase structure to function: why the "hemopexin" domain? Matrix Biol 1997; 15: 511-518. (Pubitemid 27190025)
50. Van Wart HE, Birkedal-Hansen H,. The cysteine switch: a principle of regulation of metalloproteinase activity with potential applicability to the entire matrix metalloproteinase gene family. Proc Natl Acad Sci USA 1990; 87: 5578.
51. Stawowy P, Meyborg H, Stibenz D, Stawowy NBP, Roser M, Thanabalasingam U, Veinot JP, Chretien M, Seidah NG, Fleck E,. Furin-like proprotein convertases are central regulators of the membrane type matrix metalloproteinase-pro-matrix metalloproteinase-2 proteolytic cascade in atherosclerosis. Circulation 2005; 111: 2820.
52. Nelson AR, Fingleton B, Rothenberg ML, Matrisian LM,. Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol 2000; 18: 1135.
53. Steffensen B, Hakkinen L, Larjava H,. Proteolytic events in wound-healing- coordinated interactions among matrix metalloproteinases (MMPs), integrins, and extracellular matrix molecules. Crit Rev Oral Biol Med 2001; 12: 373-398. (Pubitemid 33022035)
54. Stamenkovic I,. Extracellular matrix remodelling: the role of matrix metalloproteinases. J Pathol 2003; 200: 448-464. (Pubitemid 36818245)
55. Kyaw Tanner M, Pollitt C,. Equine laminitis: increased transcription of matrix metalloproteinase 2 (MMP 2) occurs during the developmental phase. Equine Vet J 2004; 36: 221-225. (Pubitemid 38698811)
56. Naito K, Takahashi M, Kushida K, Suzuki M, Ohishi T, Miura M, Inoue T, Nagano A,. Measurement of matrix metalloproteinases (MMPs) and tissue inhibitor of metalloproteinases-1 (TIMP-1) in patients with knee osteoarthritis: comparison with generalized osteoarthritis. Rheumatology 1999; 38: 510.
57. Soo C, Shaw WW, Zhang X, Longaker MT, Howard EW, Ting K,. Differential expression of matrix metalloproteinases and their tissue-derived inhibitors in cutaneous wound repair. Plast Reconstr Surg 2000; 105: 638.
58. Saarialho-Kere U,. Patterns of matrix metalloproteinase and TIMP expression in chronic ulcers. Arch Dermatol Res 1998; 290: 47-54.
59. Norgauer J, Hildenbrand T, Idzko M, Panther E, Bandemir E, Hartmann M, Vanscheidt W, Herouy Y,. Elevated expression of extracellular matrix metalloproteinase inducer (CD147) and membrane type matrix metalloproteinases in venous leg ulcers. Br J Dermatol 2002; 147: 1180-1186. (Pubitemid 36963025)
60. Lauer G, Sollberg S, Cole M, Flamme I, Stürzebecher J, Mann K, Krieg T, Eming SA,. Expression and proteolysis of vascular endothelial growth factor is increased in chronic wounds. J Invest Dermatol 2000; 115: 12-18. (Pubitemid 30470185)
61. Roth D, Piekarek M, Paulsson M, Christ H, Bloch W, Krieg T, Davidson JM, Eming SA,. Plasmin modulates vascular endothelial growth factor-A-mediated angiogenesis during wound repair. Am J Pathol 2006; 168: 70.
62. Impola U, Jeskanen L, Ravanti L, Syrjänen S, Baldursson B, Kähäri V,. Expression of matrix metalloproteinase (MMP) 7 and MMP 13 and loss of MMP 19 and p16 are associated with malignant progression in chronic wounds. Br J Dermatol 2005; 152: 720-726. (Pubitemid 40571305)
63. Chin D, Boyle GM, Kane AJ, Theile DR, Hayward NK, Parson PG, Coman WB,. Invasion and metastasis markers in cancers. Br J Plast Surg 2005; 58: 466-474. (Pubitemid 40645385)
64. Ramnath N, Creaven PJ,. Matrix metalloproteinase inhibitors. Curr Oncol Rep 2004; 6: 96-102. (Pubitemid 38898836)
65. Sternlicht MD, Lochter A, Sympson CJ, Huey B, Rougier JP, Gray JW, Pinkel D, Bissell MJ, Werb Z,. The stromal proteinase MMP3/stromelysin-1 promotes mammary carcinogenesis. Cell 1999; 98: 137-146. (Pubitemid 29344902)
66. D'Armiento J, DiColandrea T, Dalal SS, Okada Y, Huang M, Conney AH, Chada K,. Collagenase expression in transgenic mouse skin causes hyperkeratosis and acanthosis and increases susceptibility to tumorigenesis. Mol Cell Biol 1995; 15: 5732.
67. Overall CM, López-Otín C,. Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nat Rev Cancer 2002; 2: 657-672. (Pubitemid 37328917)
68. Armstrong DG, Jude EB,. The role of matrix metalloproteinases in wound healing. J Am Podiatr Med Assoc 2002; 92: 12.
69. Ladwig GP, Robson MC, Liu R, Kuhn M, Muir DF, Schultz GS,. Ratios of activated matrix metalloproteinase 9 to tissue inhibitor of matrix metalloproteinase 1 in wound fluids are inversely correlated with healing of pressure ulcers. Wound Repair Regen 2002; 10: 26-37. (Pubitemid 34496479)
70. Costerton J, Stewart PS, Greenberg E,. Bacterial biofilms: a common cause of persistent infections. Science 1999; 284: 1318.
71. Donlan RM,. Biofilms: microbial life on surfaces. Emerg Infect Dis 2002; 8: 881.
72. Widgerow AD,. Persistence of the chronic wound-implicating biofilm. Wound Heal South Afr 2009; 1: 5-9.
73. Waters CM, Bassler BL,. Quorum sensing: cell-to-cell communication in bacteria. Annu Rev Cell Dev Biol 2005; 21: 319-346. (Pubitemid 41740638)
74. Fuqua WC, Winans SC, Greenberg EP,. Quorum sensing in bacteria: the LuxR-LuxI family of cell density-responsive transcriptional regulators. J Bacteriol 1994; 176: 269.
75. Swift S, Throup JP, Williams P, Salmond GPC, Stewart GSAB,. Quorum sensing: a population-density component in the determination of bacterial phenotype. Trends Biochem Sci 1996; 21: 214-219. (Pubitemid 26191225)
76. Mahenthiralingam E, Campbell ME, Speert DP,. Nonmotility and phagocytic resistance of Pseudomonas aeruginosa isolates from chronically colonized patients with cystic fibrosis. Infect Immun 1994; 62: 596.
77. Simpson DA, Ramphal R, Lory S,. Genetic analysis of Pseudomonas aeruginosa adherence: distinct genetic loci control attachment to epithelial cells and mucins. Infect Immun 1992; 60: 3771.
78. Chattoraj SS, Murthy R, Ganesan S, Goldberg JB, Zhao Y, Hershenson MB, Sajjan US,. Pseudomonas aeruginosa alginate promotes Burkholderia cenocepacia persistence in CFTR knockout mice. Infect Immun 2010; 78: 984-993.
79. Learn D, Brestel E, Seetharama S,. Hypochlorite scavenging by Pseudomonas aeruginosa alginate. Infect Immun 1987; 55: 1813.
80. Krieg DP, Helmke RJ, German VF, Mangos JA,. Resistance of mucoid Pseudomonas aeruginosa to nonopsonic phagocytosis by alveolar macrophages in vitro. Infect Immun 1988; 56: 3173.
81. Berka R, Gray G, Vasil M,. Studies of phospholipase C (heat-labile hemolysin) in Pseudomonas aeruginosa. Infect Immun 1981; 34: 1071.
82. Leidal KG, Munson KL, Johnson MC, Denning GM,. Metalloproteases from Pseudomonas aeruginosa degrade human RANTES, MCP-1, and ENA-78. J Interferon Cytokine Res 2003; 23: 307-318. (Pubitemid 36760751)
83. Lyczak JB, Cannon CL, Pier GB,. Establishment of Pseudomonas aeruginosa infection: lessons from a versatile opportunist. Microbes Infect 2000; 2: 1051-1060. (Pubitemid 30664219)
84. Hornef MW, Wick MJ, Rhen M, Normark S,. Bacterial strategies for overcoming host innate and adaptive immune responses. Nat Immunol 2002; 3: 1033-1040. (Pubitemid 35363654)
85. Falanga V,. Wound bed preparation and the role of enzymes: a case for multiple actions of therapeutic agents. Wounds 2002; 14: 47-57.
86. Hall-Stoodley L, Costerton JW, Stoodley P,. Bacterial biofilms: from the natural environment to infectious diseases. Nat Rev Microbiol 2004; 2: 95-108. (Pubitemid 39490064)
87. Klausen M, Heydorn A, Ragas P, Lambertsen L, Aaes Jørgensen A, Molin S, Tolker Nielsen T,. Biofilm formation by Pseudomonas aeruginosa wild type, flagella and type IV pili mutants. Mol Microbiol 2003; 48: 1511-1524. (Pubitemid 36751058)
88. Swift S, Lynch MJ, Fish L, Kirke DF, Tomas JM, Stewart GSAB, Williams P,. Quorum sensing-dependent regulation and blockade of exoprotease production in Aeromonas hydrophila. Infect Immun 1999; 67: 5192.
89. Pearson JP, Pesci EC, Iglewski BH,. Roles of Pseudomonas aeruginosa las and rhl quorum-sensing systems in control of elastase and rhamnolipid biosynthesis genes. J Bacteriol 1997; 179: 5756.
90. Cosgrove S, Guyot N, Greene C, McElvaney N,. The effects of differential protease secretion by Pseudomonas aeruginosa under aerobic and anaerobic conditions in vitro. Am J Respir Crit Care Med 2009; 179: A1772 [1 MeetingAbstracts].
91. Hassett DJ, Cuppoletti J, Trapnell B, Lymar SV, Rowe JJ, Sun Yoon S, Hilliard GM, Parvatiyar K, Kamani MC, Wozniak DJ,. Anaerobic metabolism and quorum sensing by Pseudomonas aeruginosa biofilms in chronically infected cystic fibrosis airways: rethinking antibiotic treatment strategies and drug targets. Adv Drug Deliv Rev 2002; 54: 1425-1443. (Pubitemid 35375769)
92. Supuran CT, Scozzafava A, Mastrolorenzo A,. Bacterial proteases: current therapeutic use and future prospects for the development of new antibiotics. Expert Opin Ther Patents 2001; 11: 221-259. (Pubitemid 32117923)
93. Supuran CT, Scozzafava A, Clare BW,. Bacterial protease inhibitors. Med Res Rev 2002; 22: 329-372. (Pubitemid 34620472)
94. Kalisz H,. Microbial proteinases. In:, Scheper T, editor. Advances in biochemical engineering biotechnology. Heidelberg: Springer, 1988: 1-65.
95. Gupta R, Beg Q, Lorenz P,. Bacterial alkaline proteases: molecular approaches and industrial applications. Appl Microbiol Biotechnol 2002; 59: 15-32. (Pubitemid 34809671)
96. Wilson M, Seymour R, Henderson B,. Bacterial perturbation of cytokine networks. Infect Immun 1998; 66: 2401.
97. Schultz GS, Wysocki A,. Interactions between extracellular matrix and growth factors in wound healing. Wound Rep Regen 2009; 17: 153-162.
98. Theander T, Kharazmi A, Pedersen B, Christensen LD, Tvede N, Poulsen L, Odum N, Svenson M, Bendtzen K,. Inhibition of human lymphocyte proliferation and cleavage of interleukin-2 by Pseudomonas aeruginosa proteases. Infect Immun 1988; 56: 1673.
99. Horvat RT, Parmely MJ,. Pseudomonas aeruginosa alkaline protease degrades human gamma interferon and inhibits its bioactivity. Infect Immun 1988; 56: 2925.
100. Vollmer P, Walev I, Rose-John S, Bhakdi S,. Novel pathogenic mechanism of microbial metalloproteinases: liberation of membrane-anchored molecules in biologically active form exemplified by studies with the human interleukin-6 receptor. Infect Immun 1996; 64: 3646.
101. Hase CC, Finkelstein RA,. Bacterial extracellular zinc-containing metalloproteases. Microbiol Mol Biol Rev 1993; 57: 823.
102. Schultz DR, Miller KD,. Elastase of Pseudomonas aeruginosa: inactivation of complement components and complement-derived chemotactic and phagocytic factors. Infect Immun 1974; 10: 128.
103. Rose-John S, Heinrich PC,. Soluble receptors for cytokines and growth factors: generation and biological function. Biochem J 1994; 300 (Pt 2): 281.
104. Kayagaki N, Kawasaki A, Ebata T, Ohmoto H, Ikeda S, Inoue S, Yoshino K, Okumura K, Yagita H,. Metalloproteinase-mediated release of human Fas ligand. J Exp Med 1995; 182: 1777.
105. Crowe PD, Walter BN, Mohler KM, Otten-Evans C, Black RA, Ware CF,. A metalloprotease inhibitor blocks shedding of the 80-kD TNF receptor and TNF processing in T lymphocytes. J Exp Med 1995; 181: 1205.
106. Mullberg J, Durie FH, Otten-Evans C, Alderson MR, Rose-John S, Cosman D, Black RA, Mohler KM,. A metalloprotease inhibitor blocks shedding of the IL-6 receptor and the p60 TNF receptor. J Immunol 1995; 155: 5198.
107. Bazil V,. Physiological enzymatic cleavage of leukocyte membrane molecules. Immunol Today 1995; 16: 135.
108. Kernacki K, Fridman R, Hazlett L, Lande M, Berk R,. In vivo characterization of host and bacterial protease expression during Pseudomonas aeruginosa corneal infections in naive and immunized mice. Curr Eye Res 1997; 16: 289-297. (Pubitemid 27192512)
109. Matsumoto K, Shams NBK, Hanninen LA, Kenyon KR,. Proteolytic activation of corneal matrix metalloproteinase by Pseudomonas aeruginosa elastase. Curr Eye Res 1992; 11: 1105-1109.
110. Thibodeaux BA, Caballero AR, Marquart ME, Tommassen J, O'Callaghan RJ,. Corneal virulence of Pseudomonas aeruginosa elastase B and alkaline protease produced by Pseudomonas putida. Curr Eye Res 2007; 32: 373-386. (Pubitemid 46633863)
111. Stover C, Pham X, Erwin A, Mizoguchi S, Warrener P, Hickey M, Brinkman F, Hufnagle W, Kowalik D, Lagrou M,. Complete genome sequence of Pseudomonas aeruginosa PAO1, an opportunistic pathogen. Nature 2000; 406: 959-964.
112. Twining SS, Kirschner SE, Mahnke LA, Frank D,. Effect of Pseudomonas aeruginosa elastase, alkaline protease, and exotoxin A on corneal proteinases and proteins. Invest Ophthalmol Vis Sci 1993; 34: 2699.
113. Braun P, De Groot A, Bitter W, Tommassen J,. Secretion of elastinolytic enzymes and their propeptides by Pseudomonas aeruginosa. J Bacteriol 1998; 180: 3467.
114. Rao MB, Tanksale AM, Ghatge MS, Deshpande VV,. Molecular and biotechnological aspects of microbial proteases. Microbiol Mol Biol Rev 1998; 62: 597.
115. Kumar CG, Takagi H,. Microbial alkaline proteases: from a bioindustrial viewpoint. Biotechnol Adv 1999; 17: 561-594. (Pubitemid 30086544)
116. Underkofler L, Barton R, Rennert S,. Production of microbial enzymes and their applications. Appl Environ Microbiol 1958; 6: 212.
117. Veves A, Sheehan P, Pham HT,. A randomized, controlled trial of Promogran (a collagen/oxidized regenerated cellulose dressing) vs standard treatment in the management of diabetic foot ulcers. Arch Surg 2002; 137: 822.
118. Vin F, Teot L, Meaume S,. The healing properties of Promogran in venous leg ulcers. J Wound Care 2002; 11: 335.
119. Kakagia DD, Kazakos KJ, Xarchas KC, Karanikas M, Georgiadis GS, Tripsiannis G, Manolas C,. Synergistic action of protease-modulating matrix and autologous growth factors in healing of diabetic foot ulcers. A prospective randomized trial. J Diabetes Complications 2007; 21: 387-391. (Pubitemid 47633241)
120. Chin GA, Thigpin TG, Perrin KJ, Moldawer LL, Schultz GS,. Treatment of chronic ulcers in diabetic patients with a topical metalloproteinase inhibitor, doxycycline. Wounds 2003; 15: 315-323. (Pubitemid 37443787)
121. Timmons J,. Evaluating a new foam dressing with a healing accelerator. Wounds UK 2010; 6: 88-92.
122. Fitzgerald RH,. Collagen in wound healing: are we onto something new or just repeating the past? Foot Ankle Online J 2009; 2: 3.